Xbrane Biopharma develops biosimilars for the treatment of macular degeneration, rheumatoid arthritis, psoriasis, and cancer with a focus on making biological drugs more accessible. Self-described as a biosimilar developer.

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.

XBRA

COM:XBRANE

Xbrane Biopharma

Last Close

0.21

08/11 16:29

Market Cap

339.03M

Beta: -

Volume Today

3.11M

Avg: -

locale

market

industry

website

ipo date

peer of

competitor of

Metrics